T. Facon

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

Meletios Α. Dimopoulos, Meral Beksaç, Lotfi Benboubker et al. · Haematologica · 2013 · 39 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

Meletios Α. Dimopoulos, Robert Z. Orlowski, T. Facon et al. · Haematologica · 2014 · 31 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 ’START-C’ Study

Andreas Hochhaus, Hagop M. Kantarjian, Michele Baccarani et al. · Journal of Clinical Oncology · 2006 · 28 citations

Medicine, Pharmacology, Pharmacotherapy +13

Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard- dose imatinib: 2-year follow-up data from START-R

P. H. Rousselot, T. Facon, Ronald Paquette et al. · Journal of Clinical Oncology · 2008 · 20 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Efficacy of Dasatinib in Patients with Chronic Phase Philadelphia Chromosome-Positive CML Resistant or Intolerant to Imatinib: First Results of the CA180013 ‘START-C’ Phase II Study.

Andreas Hochhaus, Michele Baccarani, Charles L. Sawyers et al. · Blood · 2005 · 20 citations

Life Sciences, Hematology, Pharmacotherapy +9